氧氟沙星与左氧氟沙星及莫西沙星治疗呼吸道感染成本-效果分析

发布时间：2018-07-31 13:21

【摘要】：目的探讨治疗呼吸道感染使用氧氟沙星、左氧氟沙星及莫西沙星治疗的成本及效果,为临床治疗选择用药提供参考。方法选择2014年1月-2015年1月146例呼吸道感染患者,将其依据治疗方案分为A组48例、B组52例、C组46例,A组患者使用氧氟沙星治疗,B组患者使用左氧氟沙星治疗,C组患者使用莫西沙星治疗,对比3组患者治疗效果、成本、成本效果比、敏感度。结果 B组治疗总有效率为90.38%,明显高于A组的81.25%与C组的89.13%,组间对比差异有统计学意义(F=4.627,P0.05);B组治疗成本效果比、增量成本效果比分别为4.96、3.07,均低于A与C组,C组成本效果比、增量成本效果比最高,分别为9.59、55.20;敏感度分析中,B组治疗成本效果比、增量成本效果比分别为4.46、2.76,均低于A与C组,C组成本效果比、增量成本效果比最高,分别为8.63、49.68。结论左氧氟沙星治疗呼吸道感染临床有效率高、成本低,是较经济合理的抗菌药物。
[Abstract]:Objective to explore the cost and effect of ofloxacin levofloxacin and moxifloxacin in the treatment of respiratory tract infection. Methods 146 patients with respiratory tract infection from January 2014 to January 2015 were selected. The patients in group A were divided into group A (n = 48), group B (n = 52), group C (n = 52) and group A (n = 46) treated with ofloxacin. Patients in group B were treated with levofloxacin, and patients in group C were treated with moxifloxacin. Cost effectiveness ratio, sensitivity. Results the total effective rate of treatment in group B was 90.38, which was significantly higher than that in group A (81.25%) and group C (89.13). There was a statistically significant difference between the two groups (F = 4.627P). The cost-effect ratio and incremental cost-effect ratio of group B were 4.96 卤3.07, respectively, which were lower than those of group A and C, respectively. The incremental cost-effect ratio was the highest (9.59 / 55.20) and the incremental cost-effect ratio in sensitivity analysis was 4.46 / 2.76, respectively, which was lower than that in group A and C (8.63 / 49.68, respectively). Conclusion levofloxacin is a more economical and reasonable antimicrobial agent in the treatment of respiratory tract infection with high effective rate and low cost.
【作者单位】：东阳市人民医院采购中心;东阳市人民医院介入科;
【基金】：浙江省卫生厅基金资助项目(2013KYB282)
【分类号】：R56

【参考文献】